Shares in Genmab A/S show a positive technical chart pattern over the medium term. The timing to jump back on the rising trend seems good. Investors have an opportunity to buy the stock and target the DKK 2200.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Historically, the company has been releasing figures that are above expectations.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
For the past twelve months, EPS forecast has been revised upwards.
Within the weekly time frame the stock shows a bullish technical configuration above the support level at 1538 DKK
The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
The stock is close to a major daily resistance at DKK 2101, which should be gotten rid of so as to gain new appreciation potential.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the past year, analysts have significantly revised downwards their profit estimates.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.